Abby Reinhard

Four out of 6 patients with CDKL5 deficiency disorder and comorbid Lennox-Gastaut syndrome had a decrease in frequency of major motor seizures when treated with ganaxolone.

Approval permits the initiation of a phase 2 study to ascertain the efficacy of intranasal potentiated oxytocin in patients with chronic migraine.

Findings were presented at AES 2021, with 56.7% of patients reporting a 50% or greater reduction in seizure frequency.

Data suggest that roughly 1 in 100 patients hospitalized with COVID-19 infection will develop central nervous system complications.

The investigational ZZ Biotech treatment was previously evaluated in patients with acute ischemic stroke, with exploratory analyses showing a trend towards lower hemorrhage rate.

The approval expands the devices existing indications for medication-refractory essential tremor and tremor-dominant Parkinson disease.

A phase 3 trial has been initiated to further study masupirdine’s effect on agitation in patients with Alzheimer dementia.

After being granted FDA clearance, the medical device is approved for commercial distribution in the US for cognitive assessments in dementia studies.

Data show a clinical benefit via a reduction in brain amyloid as early as 3 months in the open-label extension period.

CBT-I treatment was found to provide an overall benefit in preventing incident and recurrent major depression in the patient population, highlighting the need for community-level screening for insomnia.

The study is the first and only to compare the 2 anticalcitonin gene-related peptide medicines for migraine preventive treatment.

Although not associated with diagnosis, investigators did conclude that substantial/very severe impact of headache attacks and anxiety were correlated with presence of insomnia.

The NeurologyLive® team has compiled a roundup of our discussions with leaders in the multiple sclerosis field following the 2021 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

Both fatigue and sleep quality were identified as potential risk factors linking sleep duration and self-rated health.

Ali Rezai, MD, executive chair at the Rockefeller Neuroscience Institute at West Virginia University, outlined early data from a clinical trial utilizing focused ultrasound to open the blood-brain barrier in patients with mild AD.

Contrary to previous expectations, 30 minutes of social media before bedtime did not significantly increase arousal or disturb sleep for study participants.

The guideline updates previous recommendations for dopaminergic medications published in 2002, integrating new medications and formulations.

Ali Rezai, MD, executive chair of the Rockefeller Neuroscience Institute at West Virginia University, provided an overview of FUS technology and its use in opening the blood-brain barrier.

A higher incidence of gastrointestinal events was observed in the treatment group compared with placebo, similar to what was seen in clinical trials of AMX0035 in amyotrophic lateral sclerosis.

Results outline secondary end points, which follow previously reported data on the AMBAR study’s primary end points, including delay in cognitive and functional decline in patients with AD.

Despite being discontinued early, patients in the high-dose group of the PLEO-CMT trial experienced statistically significant improvement in Overall Neuropathy Limitations Scale total score.

A stronger association between the 2 conditions was seen in younger patients and men with epilepsy than their counterparts in the matched cohort of more than 9000 individuals.

A presentation at CTAD 2021 included data from 5 patients enrolled in a phase 2a trial to evaluate neurocognitive, imaging, and safety outcomes of the therapeutic approach in early AD dementia.

Findings presented at CTAD 2021 included data from surveyed participants with dementia and healthy volunteers about starting in-person or remote research.

The new registry will collect routine clinical practice data from the care of patients with Alzheimer disease who are taking an FDA-approved disease-modifying therapy.

Study of semorinemab in a larger mITT population confirmed statistically significant reduction in rate of cognitive decline in patients with Alzheimer disease, compared with placebo, but failed to achieve other end points.

The trial is anticipated to enroll 300 patients with amyotrophic lateral sclerosis in Europe to evaluate the safety and efficacy of oral edaravone.

Data suggest the need to investigate sleep-disordered breathing even before lung function is compromised in patients with cystic fibrosis.

A total of 12 studies evaluating children and adolescents with nonepileptic seizures were included, with both top-down and bottom-up approaches employed.

A total of 14 children and their mothers were evaluated in the study, and although improvements in sleep scores were also reported, they were not statistically significant.